Skip to main content

Month: August 2024

uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

~ Announced RMAT designation for AMT-130 in Huntington’s disease and positive interim Phase I/II data demonstrating the slowing of disease progression and reductions in a key biomarker of neurodegeneration; Meeting with FDA expected in the second half of 2024 to discuss potential for expedited clinical development ~ ~ Initiated patient screening for three additional Phase I/II studies in mesial temporal lobe epilepsy, SOD1 ALS, and Fabry disease ~ ~ Today, announced an organizational restructuring intended to streamline operations; Together with the recent sale of the Lexington manufacturing facility, these changes are expected to reduce headcount by 65% and lower recurring cash burn by $75 million per year including savings from the retirement of $50 million of debt ~ ~ Strong cash position of approximately $524 million as of June 30,...

Continue reading

BigCommerce Announces Second Quarter 2024 Financial Results

Second Quarter Total Revenue of $81.8 Million, an Increase of 8% Versus Prior Year. Total ARR of $345.8 Million, an Increase of 4% Versus Prior Year. Enterprise ARR of $253.8 Million, an Increase of 7% Versus Prior Year AUSTIN, Texas, Aug. 01, 2024 (GLOBE NEWSWIRE) — BigCommerce Holdings, Inc. (“BigCommerce”) (Nasdaq: BIGC), an open SaaS, composable ecommerce platform for fast-growing and established B2C and B2B brands and retailers, today announced financial results for its second quarter ended June 30, 2024. “The second quarter delivered results consistent with our top- and bottom-line plans,” said Brent Bellm, CEO of BigCommerce. “Revenue finished just under $82 million, up over 8% year-over-year, with profitability exceeding our expectations and operating cash flow of nearly $12 million. We delivered our largest sequential...

Continue reading

TransAlta Reports Second Quarter 2024 Results

CALGARY, Alberta, Aug. 01, 2024 (GLOBE NEWSWIRE) — TransAlta Corporation (“TransAlta” or the “Company”) (TSX: TA) (NYSE: TAC) today reported its financial results for the three and six months ended June 30, 2024, demonstrating strong financial performance and reaffirming its 2024 outlook. Second Quarter 2024 Financial Highlights TransAlta’s second quarter results exceeded expectations and delivered strong free cash flow and solid operating performance. The Company delivered Free Cash Flow (“FCF”)(1) per share of $0.57, which was firmly supported by its hedging and asset optimization strategies given the expected decline in Alberta spot power prices year over year, milder weather, lower natural gas prices and incremental generation from the addition of new natural gas, wind and solar supply in the market. Highlights...

Continue reading

TC Energy reports strong second quarter 2024 operating and financial results

Southeast Gateway pipeline project achieves over 98 per cent offshore pipeline installation CALGARY, Alberta, Aug. 01, 2024 (GLOBE NEWSWIRE) — TC Energy Corporation (TSX, NYSE: TRP) (TC Energy or the Company) released its second quarter results today. François Poirier, TC Energy’s President and Chief Executive Officer commented, “During the first six months of 2024, we delivered 10 per cent year-over-year growth in comparable EBITDA1 and approximately 35 per cent growth in segmented earnings.” Poirier continued, “We continued to advance multiple strategic initiatives aimed at maximizing the long-term value of our assets and furthering our deleveraging efforts. We announced a historic equity ownership agreement that will enable Indigenous Communities to become owners in the NGTL and Foothills Systems, achieved a successful shareholder...

Continue reading

Record Results by Willis Lease Finance Corporation with Second Quarter Pre-tax Income of $57.9 million. Willis Declares First, Regular Quarterly Dividend of $0.25 Per Share.

COCONUT CREEK, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) — Willis Lease Finance Corporation (NASDAQ: WLFC) (“WLFC” or the “Company”) today reported record second quarter total revenues of $151.1 million and record quarterly pre-tax income of $57.9 million. The Company also announced its first regular quarterly dividend of $0.25 per share, expected to be paid on August 21, 2024, with a record holder date of August 12, 2024. For the three months ended June 30, 2024, aggregate, core lease rent and maintenance reserve revenues were at an all-time high of $118.8 million, up 32% as compared to $89.8 million in 2023. The growth was predominantly driven by core, recurring lease and maintenance revenues associated with a strong, resurging aviation marketplace, and airlines leveraging the Company’s leasing, parts and maintenance capabilities...

Continue reading

ADMA Biologics to Report Second Quarter 2024 Financial Results on August 8, 2024

Conference Call Scheduled for August 8, 2024, at 4:30 p.m. ET RAMSEY, N.J. and BOCA RATON, Fla., Aug. 01, 2024 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report second quarter 2024 financial results on August 8, 2024, after the U.S. financial markets close. ADMA’s management team will host a live conference call and audio webcast on that date at 4:30 p.m. ET to discuss its financial results and other Company updates. To access the conference call seamlessly, participants are required to register for the call here to receive the dial-in numbers and unique PIN. It is recommended that you join approximately 10 minutes prior to the event start...

Continue reading

Enthusiast’s Luminosity Partners With Amazon Prime For Second Activation of the Year, ‘Coins & Rings’

After the success of its initial collaboration, Amazon Prime returns for new activation with Enthusiast Gaming, Luminosity’s ‘Coins and Rings’ to be held on August 1st LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) — Enthusiast Gaming Holdings Inc. (“Enthusiast Gaming” or the “Company”) (TSX: EGLX), a leading gaming media and entertainment company, today announced that, in partnership with Amazon Prime, its esports team, Luminosity, will host an invitational event on August 1st featuring a variety of North American content creators. Luminosity’s ‘Coins and Rings’ will be a one-day event hosted by Luminosity content creator Zak ‘Coney‘ Zeeks and feature eight content creators divided into two teams. On August 1st, the content creators will compete in various game modes in Mario & Sonic at The Olympic Games, with final scores...

Continue reading

Destination XL Group, Inc. to Announce Second Quarter 2024 Financial Results on August 29, 2024

Company to Webcast Conference Call Live at 9:00 a.m. ET CANTON, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — Destination XL Group, Inc. (NASDAQ: DXLG), the leading integrated commerce retailer of Big + Tall men’s clothing and shoes, announced today it will release its second quarter of fiscal 2024 financial results before the market opens on Thursday, August 29, 2024. President and Chief Executive Officer Harvey Kanter and Executive Vice President, Chief Financial Officer, and Treasurer Peter Stratton will host a conference call the same morning at 9:00 a.m. ET to discuss the results. Participants can join by conference call or webcast: Conference Call To participate in the conference call, please pre-register at:https://register.vevent.com/register/BI648dfc60556f441ea1ca4ecc8af13faa. Upon registering, you will receive a dial-in number...

Continue reading

Passage Bio Out-licenses Three Pediatric Gene Therapy Programs to GEMMA Biotherapeutics and Enters New Research Collaboration

Granted exclusive, worldwide rights for the development and commercialization of PBGM01 for GM1 gangliosidosis, PBKR03 for Krabbe disease, and PBML04 for metachromatic leukodystrophy to GEMMA Biotherapeutics, a new company co-founded by Dr. James M. Wilson Entered new strategic research and collaboration agreement with GEMMA Biotherapeutics to advance genetic medicines for CNS indications, including Huntington’s disease Transaction expected to extend operating cash runway to the end of Q2 2026 PHILADELPHIA, Aug. 01, 2024 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that it has entered into a series of agreements to out-license its three clinical-stage pediatric lysosomal storage disease...

Continue reading

C4 Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Preliminary Monotherapy Data from the Ongoing CFT1946 Phase 1 Trial in BRAF V600X Solid Tumors to be Presented at ESMO Congress 2024; Initiated Monotherapy Expansion Cohort in Melanoma and Combination Cohort with Cetuximab in Colorectal Cancer Cemsidomide Phase 1 Trial in Multiple Myeloma and non-Hodgkin’s Lymphoma Continues to Progress through Dose Escalation; Data on Track for Q4 2024 Cash, Cash Equivalents and Marketable Securities of $295.7 million as of June 30, 2024; Expected to Provide Runway into 2027 WATERTOWN, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) — C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, reported financial results today for the second quarter ended June 30, 2024, as well as recent business highlights. “Our strong...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.